Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience

Takeda, Maiko; Kasai, Takahiko; Naito, Maiko; Tamiya, Akihiro; Taniguchi, Yoshihiko; Saijo, N.; Naoki, Yoko; Okishio, Kyoichi; Shimizu, Shigeki; Kojima, Kensuke; Nagoya, Akihiro; Sakamoto, Tetsuki; Utsumi, Tomoki; Yoon, Hyungeun; Matsumura, Akira; Atagi, Shinji

doi:10.1177/1179554918821314

Cited by 8 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study indicated that large tumor size and CT texture of pSD in LUAD were correlated with high PD-L1 expression, consistent with the results of previous studies [13][14][15]. Furthermore, large tumor size and pSD of LUAD also indicated high Ki67 expression, suggesting a relationship between the expressions of Ki67 and PD-L1.…”

Section: Discussionsupporting

confidence: 91%

“…This study revealed that the expression of PD-L1 was correlated with male smoking, high Ki67 expression, and wild-type EGFR in LUAD. Q. Zhu et al also revealed an association of PD-L1 with male gender and smoking history, supported by several other studies [14,16,17,29,30]. Q. Chen et al revealed that EGFR-mutated patients showed relatively lower PD-L1 expression than wild-type patients [17] Furthermore, it has been repetitively indicated that EGFR wild-type tumors were significantly more likely to express PD-L1 than EGFR-mutated tumors [13,17,18,[31][32][33].…”

Section: Discussionmentioning

confidence: 61%

“…The literature suggests that PD-L1 expression is correlated with male gender, smoking [14,15], high Ki67 expression [16], wild-type EGFR status [13,17,18], and absence of GGO with CT texture of LUAD [3]. However, the dominant factors remain undetermined.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Factors correlating the expression of PD-L1

Lu,

Wang,

Liu

2024

BMC Cancer

View full text Add to dashboard Cite

Objective PD-L1 was an important biomarker in lung adenocarcinoma. The study was to confirm the most important factor affecting the expression of PD-L1 remains undetermined. Methods The clinical records of 1045 lung adenocarcinoma patients were retrospectively reviewed. The High-Resolution Computed Tomography (HRCT) scanning images of all the participants were analyzed, and based on the CT characteristics, the adenocarcinomas were categorized according to CT textures. Furthermore, PD-L1 expression and Ki67 index were detected by immunohistochemistry. All patients underwent EGFR mutation detection. Results Multivariate logistic regression analysis revealed that smoking (OR: 1.73, 95% CI: 1.04–2.89, p = 0.004), EGFR wild (OR: 1.52, 95% CI: 1.11–2.07, p = 0.009), micropapillary subtypes (OR: 2.05, 95% CI: 1.46–2.89, p < 0.0001), and high expression of Ki67 (OR: 2.02, 95% CI: 1.44–2.82, p < 0.0001) were independent factors which influence PD-L1 expression. In univariate analysis, tumor size > 3 cm and CT textures of pSD showed a correlation with high expression of PD-L1. Further analysis revealed that smoking, micropapillary subtype, and EGFR wild type were also associated with high Ki67 expression. Moreover, high Ki67 expression was observed more frequently in tumors of size > 3 cm than in tumors with ≤ 3 cm size as well as in CT texture of pSD than lesions with GGO components. In addition, multivariate logistic regression analysis revealed that only lesions with micropapillary components correlated with pSD (OR: 3.96, 95% CI: 2.52–5.37, p < 0.0001). Conclusion This study revealed that in lung adenocarcinoma high Ki67 expression significantly influenced PD-L1 expression, an important biomarker for immune checkpoint treatment.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 61%

See 1 more Smart Citation

Factors correlating the expression of PD-L1

Lu,

Wang,

Liu

2024

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…The frequency of PD-L1 ≥ 50% was 26.0-34.0% in previous pivotal studies and 29.0% in a single-center study in Japan. 12,14,29 In our study, the proportion of PD-L1 ≥ 50% in the overall analysis set was 32.1%, whereas the proportion of PD-L1 ≥ 50% in the cachexia group was as high as 48.0%. Considering the possibility of selection bias caused by assessing the PD-L1 TPS only in patients with NSCLC who received chemoimmunotherapy, we assessed the PD-L1 TPS in patients with NSCLC who received chemotherapy in a single center.…”

Section: Discussionmentioning

confidence: 47%

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study

et al. 2021

View full text Add to dashboard Cite

Although previous studies suggest that cancer cachexia is a poor prognostic factor for immune checkpoint inhibitor monotherapy, the impact of cancer cachexia on chemoimmunotherapy is unclear. We investigated the impact of cancer cachexia on the therapeutic outcomes of chemoimmunotherapy for non-small cell lung cancer (NSCLC). We retrospectively analyzed patients' medical records with NSCLC who received chemoimmunotherapy in 12 institutions in Japan between January and November 2019. We defined cancer cachexia as weight loss exceeding 5% of the total body weight or a body mass index of < 20 kg/m 2 and weight loss of more than 2% of the total body weight within 6 months before chemoimmunotherapy initiation, with laboratory results exceeding reference values. This study enrolled 235 patients with NSCLC, among whom 196 were eligible for analysis, and 50 (25.5%) met the criteria for cachexia diagnosis. Patients with cancer cachexia had a significantly higher frequency of a programmed death-ligand 1 (PD-L1) expression of ≥ 50% (48%, p = .01) and shorter progression-free survival (PFS; logrank test: p = .04) than patients without cachexia. There was no significant difference in overall survival (OS) between the cachexia and no-cachexia groups (log-rank test: p = .14). In the PD-L1 ≥ 50% population, there was no significant difference in PFS and OS (log-rank test: p = .19 and p = .79, respectively) between patients with NSCLC in the cachexia or no-cachexia groups. Cancer cachexia might be a poor prognostic factor in patients with NSCLC receiving chemoimmunotherapy.

show abstract

“…Further limitations include the fact that dynamic, real-time detection of PD-L1 content in vivo is not possible, and there is also controversy surrounding the use of archived vs. fresh specimens for testing. Takeda et al evaluated the expression of PD-L1 in archived and fresh samples and found that it was significantly lower in archived specimens 79 . However, the KEYNOTE-010 trial 80 and the FIR study 81 demonstrated that either fresh or archived tissues could be reliably assessed for PD-L1 status by IHC.…”

Section: Detection Methodsmentioning

confidence: 99%

Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy

Zhang¹,

Wu²,

Zhao³

et al. 2023

J. Cancer

View full text Add to dashboard Cite

Programmed death-1 is a protein found on the surface of immune cells that can interact with its ligand, programmed death-ligand 1 (PD-L1), which is expressed on the plasma membrane, the surface of secreted cellular exosomes, in cell nuclei, or as a circulating soluble protein. This interaction can lead to immune escape in cancer patients. In clinical settings, PD-L1 plays an important role in tumor disease diagnosis, determining therapeutic effectiveness, and predicting patient prognosis. PD-L1 inhibitors are also essential components of tumor immunotherapy. Thus, the detection of PD-L1 levels is crucial, especially in the era of precision cancer therapy. In recent years, innovations have been made in traditional immunoassay methods and the development of new immunoassays for PD-L1 detection. This review aims to summarize recent research progress in tumor PD-L1 detection technology and highlight the clinical applications of PD-L1.

show abstract

Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience

Cited by 8 publications

References 31 publications

Factors correlating the expression of PD-L1

Factors correlating the expression of PD-L1

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study

Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy

Contact Info

Product

Resources

About